GrowBLOX Sciences’ patent-pending technology for medical-grade cannabis comes off production line

GrowBLOX Sciences, Inc. (OTCQB: GBLX) announced today that the first of its patent pending proprietary agricultural indoor growing system for medical-grade cannabis has come off the production line. GrowBLOX Sciences has developed proprietary growing technology for environmentally controlled, indoor agricultural chambers. This is the first of the newest generation of GrowBLOX's that are expected to arrive at The Company's headquarters in Nevada by mid-June. The Company anticipates beginning quality control on both mechanics and its proprietary monitoring and report-building software before starting the full production line. The quality control test will be run by Chief Scientist and Botanist, Ulrich Reimann-Philipp, Ph.D.

"GrowBLOX Sciences is in an exciting phase in its development and we have positioned ourselves to move forward with our patent pending technology in order to change the way indoor growing methodologies take place. We are thrilled the fist indoor growing chamber is off the line and our Chief Scientist and Botanist is ready to begin quality control testing. From our indoor growing chambers to our monitoring and reporting systems, we believe our proprietary technology will impact the future of medical-grade products in Nevada," said GrowBLOX CEO, Craig Ellins.

As GrowBLOX Sciences awaits the arrival of its first indoor growing chamber off the production line, The Company is also awaiting approval on its licensing from Clark County, Nevada for their cultivation and dispensary licenses. The Company has applied for three licenses, one for cultivation and two for dispensaries.

Source:

GrowBLOX Sciences, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024